Clinical Research Directory

Inclusion Criteria: ≥18 years old NHL, HL or breast cancer diagnosis Scheduled to undergo chemotherapy including ≥ 240 mg/k2 cumulative dose of anthracyclines. Pre-chemo LVEF \>40% on screening echocardiography. Presence of ≥1 of the following risk factors for developing cardiotoxicity: Previous coronary artery disease (any of the following): Previous coronary revascularisation (PCI or CABG) or Medical history of previous significant nonrevascularized coronary stenosis Previous Acute Coronary Syndrome / Acute Myocardial Infarction with a LVEF \> 40 LVEF 41-54% Age ≥ 65 years old Previous diagnosis of arterial hypertension (with or without treatment) Chronic kidney disease (estimated glomerular filtration rate \<60ml/min/1.73m2) Current or former smoker. Obesity (BMI≥30 kg/m2) LVH on screening echocardiography (LV thickness ≥12mm). High alcohol intake (≥21 alcoholic beverages per week) Sinus rhythm on screening ECG Previous diagnosis of diabetes (except those treated with sulfonylureas or those with neuropathy) Previous non-anthracycline-based chemotherapy Signed Informed Consent Form (ICF) Exclusion Criteria: * History of any of the following diseases: * Any cancer who received anthracyclines treatment before the index episode. * Previous clinical diagnosis of heart failure. * Permanent atrial fibrillation (AF). * Severe valvular or sub-valvular heart disease. * Severe peripheral arterial disease in the upper extremities or arteriovenous (AV) shunt in the arm selected for RIPC. * Clinical diagnosis of diabetes neuropathy * Contraindication for CMR: * Severe claustrophobia. * Any device which is known to threaten or pose hazard in all MR environments (http://www.mrisafety.com/). * Patients with implanted biomedical cardiac devices: pacemakers, ICDs or CRT. * Severe thrombocytopenia (platelets \<50,000/µL) on any blood test within the previous 3 months. * Patients participating in other clinical trials. * Impossibility to consent or undergo study follow-ups.